EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale and Design of the HF-REVERT Trial

Johann Bauersachs, Scott D Solomon, Stefan D Anker, Isabel Antorrena-Miranda, Sandor Batkai, Janika Viereck, Steffen Rump, Gerasimos Filippatos, Ulrich Granzer, Piotr Ponikowski, Rudolf A de Boer, Orly Vardeny und 2 weitere

European Journal of Heart Failure · 01.03.2024 · 26 (3) · 674-682

DOI: 10.1002/ejhf.3139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 25.01.2024. Verfasst von Johann Bauersachs und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Myocardial Infarction, Stroke Volume. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Inhibition of microRNA (miR)-132 effectively prevents and reverses adverse cardiac remodelling, making it an attractive heart failure (HF) target. CDR132L, a synthetic antisense oligonucleotide selectively blocking pathologically elevated miR-132, demonstrated beneficial effects on left ventricular (LV) structure and function in relevant preclinical models, and was safe and well tolerated in a Phase 1b study in stable chronic HF patients. Patients with acute myocardial infarction (MI) and subsequent LV dysfunction and remodelling have limited therapeutic options, and may profit from early CDR132L treatment.

Methods

The HF-REVERT (Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction after Myocardial Infarction) evaluates the efficacy and safety of CDR132L in HF patients post-acute MI (n = 280), comparing the effect of 5 and 10 mg/kg CDR132L, administered as three single intravenous doses 28 days apart, in addition to standard of care. Key inclusion criteria are the diagnosis of acute MI, the development of systolic dysfunction (LV ejection fraction ≤45%) and elevated N-terminal pro-B-type natriuretic peptide. The study consists of a 6-month double-blinded treatment period with the primary endpoint LV end-systolic volume index and relevant secondary endpoints, followed by a 6-month open-label observation period.

Conclusion

The HF-REVERT trial may underpin the concept of miR-132 inhibition to prevent or reverse cardiac remodelling in post-MI HF. The results will inform the design of subsequent outcome trials to test CDR132L in HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionStroke VolumeHumansMaleFemaleHeart FailureVentricular Dysfunction, LeftTreatment OutcomeMicroRNAsVentricular RemodelingMiddle AgedAgedOligonucleotides, AntisenseDouble-Blind MethodVentricular Function, LeftClinical Trials, Phase II as TopicMulticenter Studies as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

CDR132LCardiac remodellingContractile functionPhase 2 trial designPost‐myocardial infarction heart failuremicroRNAs

Substanzen

MicroRNAsOligonucleotides, Antisense

Autor:innen und Institutionen

  • Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Cardiology (CVK) of German Heart Center Charité, BIH Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Ger…
  • Cardiology Department, Hospital Universitario la Paz-Idipaz, Madrid, Spain.
  • Cardior Pharmaceuticals GmbH, Hannover, Germany.
  • Department of Cardiology, School of Medicine, Athens University Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece.

Zitieren

APA

Bauersachs, J., Solomon, S. D., Anker, S. D., Antorrena-Miranda, I., Batkai, S., Viereck, J., Rump, S., Filippatos, G., Granzer, U., Ponikowski, P., de Boer, R. A., Vardeny, O., Hauke, W., & Thum, T. (2024). Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale and Design of the HF-REVERT Trial. European Journal of Heart Failure, 26(3), 674-682. https://doi.org/10.1002/ejhf.3139

Vancouver

Bauersachs J, Solomon SD, Anker SD, Antorrena-Miranda I, Batkai S, Viereck J, et al. Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale and Design of the HF-REVERT Trial. European Journal of Heart Failure. 2024;26(3):674-682. doi:10.1002/ejhf.3139

BibTeX
@article{Bauersachs2024,
  author = {Bauersachs, Johann and Solomon, Scott D and Anker, Stefan D and Antorrena-Miranda, Isabel and Batkai, Sandor and Viereck, Janika and Rump, Steffen and Filippatos, Gerasimos and Granzer, Ulrich and Ponikowski, Piotr and de Boer, Rudolf A and Vardeny, Orly and Hauke, Wilfried and Thum, Thomas},
  title = {Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale and Design of the HF-REVERT Trial},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {3},
  pages = {674--682},
  doi = {10.1002/ejhf.3139}
}
Kostenlos starten →